Secretory diarrhea is the leading cause of death in children less than 5 years of age in developing countries, and a frequent and most unwelcome diagnosis for many adults that is made, on average, up ...

Aim is to develop a CFTR ion channel blocker to help prevent fluid loss. Novartis and the Institute for OneWorld Health signed a three-year collaboration to develop a treatment for secretory diarrhea ...

Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases. In the December 28 issue of the Journal of ...

Osmotic Diarrhea • Drugs draws water and ions into intestinal lumen Artificial sweeteners, alpha glucosidase inhibitors, Mg laxative, polyethylene glycol, ACE inhibitors Secretory Diarrhea • Drug ...

Osmotic diarrhea is caused by the presence of unabsorbed nutrients in the gastrointestinal tract, frequently secondary to intestinal damage leading to impairment in digestion or absorption. The most ...

Rotavirus may not be on the hot list of viruses dominating headlines, but globally, it still tops the charts as the leading cause of severe, dehydrating diarrhea in children younger than 5 years, ...

In a development that may lessen the epidemic of diarrhea-related deaths among children in developing countries, scientists have discovered a novel compound that might lead to an inexpensive, ...

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID ...

SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc.

Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases. The novel peptide, called GaTx1, can ...

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID ...